Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the sale, the chief financial officer directly owned 1,467,635 shares of the company’s stock, valued at $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kamran Alam also recently made the following trade(s):

• On Monday, January 26th, Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total value of $109,943.89.

Taysha Gene Therapies Trading Down 5.9%

Shares of TSHA stock opened at $4.48 on Thursday. The business has a 50-day moving average price of $5.10 and a two-hundred day moving average price of $4.09. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $6.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.23 billion, a P/E ratio of -13.58 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Robert W. Baird raised their price objective on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Wells Fargo & Company increased their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, UBS Group set a $11.00 price target on Taysha Gene Therapies in a research report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently modified their holdings of the business. Marex Group plc purchased a new position in Taysha Gene Therapies during the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $31,000. ST Germain D J Co. Inc. increased its stake in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares during the period. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Taysha Gene Therapies in the third quarter worth $40,000. 77.70% of the stock is owned by institutional investors.

More Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Analyst outlook remains constructive: several firms have raised price targets and reiterated buy/outperform ratings (Wells Fargo, Robert W. Baird, Needham, JMP, Citizens/JMP). This supports upside vs. current levels.
• Positive Sentiment: Notable institutional activity: multiple funds reported adding or building positions (MarketBeat summary highlights large additions), which can be a longer‑term vote of confidence.
• Neutral Sentiment: Recent earnings matched estimates (Q3 EPS -$0.09), and consensus expects continued losses this year — typical for a clinical‑stage biotech; no near‑term revenue catalysts were reported. Earnings & Consensus
• Neutral Sentiment: Technical/market context: shares had elevated volume vs. average and sit between the 50‑day (~$5.09) and 200‑day (~$4.08) moving averages; valuation remains typical for pre‑revenue gene therapy names (negative P/E). Quote & Technicals
• Negative Sentiment: Insider selling — CFO Kamran Alam: sold 78,968 shares (Jan. 23) and 23,849 shares (Jan. 26), reducing his stake; the Jan. 26 sale filed with the SEC. CFO Form 4
• Negative Sentiment: Insider selling — CEO Sean P. Nolan: sold 136,789 shares (Jan. 23) and 41,312 shares (Jan. 26), reducing his ownership; filings are public with the SEC. CEO Form 4
• Negative Sentiment: Insider selling — director Sukumar Nagendran: sold 89,132 shares (Jan. 23) and 26,918 shares (Jan. 26), further insider reductions reported. Director Form 4

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.